DOCETAXEL IS GIVEN BY INTRAVENOUS INFUSION IN GLUCOSE 5% OR SODIUM CHLORIDE 0.9% AT A CONCENTRATION NOT EXCEEDING 0.74 MG/ML. INFUSION IS NORMALLY OVER 1 HOUR.
BREAST CANCER : AFTER FAILURE OF PREVIOUS CHEMOTHERAPY IS 60 TO 100 MG/M2 ONCE EVERY 3 WEEKS. A DOSE OF 75 MG/M2 ONCE EVERY 3 WEEKS IS GIVEN IN COMBINATION THERAPY WITH DOXORUBICIN, OR CAPECITABINE, OR WHEN USED AS ADJUVANT THERAPY WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE. WHEN USED WITH TRASTUZUMAB, DOCETAXEL IS GIVEN AT A DOSE OF 100 MG/M2 ONCE EVERY 3 WEEKS.
NON-SMALL CELL LUNG CANCER : IS 75 MG/M2 ONCE EVERY 3 WEEKS, FOR BOTH FIRST-LINE COMBINATION THERAPY AND MONOTHERAPY AFTER FAILURE OF PREVIOUS CHEMOTHERAPY. PREMEDICATION WITH AN ORAL CORTICOSTEROID, SUCH AS DEXAMETHASONE 16 MG DAILY, FOR 3 DAYS STARTING 1 DAY BEFORE DOCETAXEL IS RECOMMENDED.
PROSTATE CANCER : THE DOSE OF DOCETAXEL IS 75 MG/M2 ONCE EVERY 3 WEEKS, WITH PREDNISONE OR PREDNISOLONE 5 MG ORALLY TWICE DAILY GIVEN CONTINUOUSLY. THE USE OF PREDNISONE OR PREDNISOLONE REDUCES THE NEED FOR A PREMEDICATION CORTICOSTEROID; DEXAMETHASONE 8 MG MAY BE GIVEN AT 12 HOURS, 3 HOURS, AND 1 HOUR BEFORE DOCETAXEL.
REGULAR BLOOD COUNTS ARE REQUIRED, AND DOSAGE IN SUBSEQUENT COURSES SHOULD BE REDUCED IN PATIENTS WHO EXPERIENCE SEVERE OR FEBRILE NEUTROPENIA OR SEVERE CUTANEOUS REACTIONS OR PERIPHERAL NEUROPATHY